Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial (Q36817105)

16 August 2017

1 reference

title

Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial (English)

1 reference

16 August 2017

3

1 reference

16 August 2017

Roberta Ferraldeschi

1

1 reference

16 August 2017

Nick Thatcher

series ordinal

2

1 reference

16 August 2017

publication date

1 May 2007

1 reference

Expert Review of Anticancer Therapy

16 August 2017

published in

1 reference

16 August 2017

volume

7

1 reference

16 August 2017

issue

5

1 reference

16 August 2017

page(s)

635-640

1 reference

Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Randomized phase II trial of pemetrexed combined with either cisplatin or carboplatin in untreated extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Pemetrexed disodium: a novel antifolate clinically active against multiple solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Activity of the multitargeted antifolate LY231514 in the human tumor cloning assay.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of randomized trials of a cisplatin-containing regimen versus a regimen without this alkylating agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

A systematic review of the role of etoposide and cisplatin in the chemotherapy of small cell lung cancer with methodology assessment and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naive patients with extensive-disease small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Efficient palliation in patients with small-cell lung cancer by a combination of paclitaxel, etoposide and carboplatin: quality of life and 6-years'-follow-up results from a randomised phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

Phase I-II study of amrubicin and cisplatin in previously untreated patients with extensive-stage small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2F14737140.7.5.635

21 January 2018

Identifiers

DOI

10.1586/14737140.7.5.635

1 reference

16 August 2017

1 reference